Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages
Megan E. Barra, Alvin S. Das, Bryan D. Hayes, Eric S. Rosenthal, Rachel Rosovsky, Lanting Fuh, Aman B. Patel, Joshua N. Goldstein, Russel J. Roberts
Topics & Concepts
RivaroxabanApixabanProthrombin complex concentrateMedicinePROTHROMBIN COMPLEXAnesthesiaInternal medicineAtrial fibrillationWarfarinCoagulationAtrial Fibrillation Management and OutcomesIntracerebral and Subarachnoid Hemorrhage ResearchBlood Coagulation and Thrombosis Mechanisms